CLEVELAND, OH – September 6, 2016
BioMotiv and Biogen have expanded their existing strategic partnership to include the development of ophthalmology medicines. The expansion includes an additional $10 million Biogen investment into BioMotiv, bringing BioMotiv’s total capitalization to $145 million.

Click here to read more.